Tags : SYROS

Santhera Reports Results of Idebenone in SYROS Study for Duchenne

Shots: The SYROS study involves assessing of respiratory function evolution during periods of treatment with idebenone (900 mg/day) (On-Idebenone) compared to period without idebenone treatment (Off-Idebenone) in 18 patients with DMD not using glucocorticoids under Expanded Access Programs following P-III DELOS study, published in Neuromuscular Disorders The SYROS study results demonstrated long-term efficacy in slowing […]Read More

Santhera to Present Result of DELOS & SYROS Study at

Shots: The P-III DELOS study involves assessing of Idebenone (900 mg/day) vs PBO in 64 patients with Duchenne muscular dystrophy (DMD) for 52wks. & P-II DELPHI study with 2-year extension study (DELPHI-E). SYROS study involves assessing of Idebenone (900 mg/day) in 18 patients under Expanded Access Programs (EAPs) who completed the DELOS study The P-III […]Read More